Last updated: June 18, 2026
Apixaban Suppliers: API Manufacturers, Contract Manufacturing Options, and Supply-Chain Risk Map
Apixaban (Eliquis; active ingredient apixaban) is sourced through a tiered supply chain. At the API level, suppliers typically provide apixaban bulk drug substance under cGMP/ICH-aligned dossiers and DMFs. Final dose manufacturing is usually handled by large global CDMOs and specialized solid-dose facilities with validated particle-size and impurity controls to meet FDA specs.
This page consolidates the apixaban supplier landscape by function: API manufacturers, key intermediates and outsourcing partners (where publicly identifiable), and common CDMO roles for tablet production.
What suppliers make apixaban API for commercial supply?
Apixaban API is manufactured by a mix of multinational and Asia-based producers that hold DMFs for apixaban (or related process registrations) and support commercial scale batches with impurity profiling, polymorph/particle-size controls, and validated crystallization and filtration steps.
At a practical procurement level, buyers generally engage:
- API manufacturers with an apixaban DMF suitable for FDA commercial importation
- API and intermediate suppliers that feed integrated synthesis and purification packages
- CDMOs that either (a) receive API and perform tableting and packaging or (b) run end-to-end solid dose manufacturing from API receipt and QC release
How do apixaban suppliers typically structure contracts?
Supplier contracts often separate:
- API supply agreement (bulk apixaban, with spec/impurity acceptance criteria and change-control commitments)
- Tech transfer and process validation (including polymorph and impurity controls)
- Quality and regulatory support (DMF bridging, CEP if applicable, batch release packages)
- OOS/OOT and stability commitments (ongoing stability program, comparability, and lifecycle management)
Which companies supply apixaban API (bulk drug substance)?
A complete, verified list of apixaban API suppliers cannot be produced from the supplied prompt alone.
What DMF holders supply apixaban to the US market?
A complete, verified mapping of apixaban DMF holders to specific suppliers cannot be produced from the supplied prompt alone.
How do apixaban tablet CDMOs source API and manage regulatory compliance?
Apixaban tablets are solid oral dosage forms that require tight control over:
- API impurity profile and total impurities
- Particle size distribution and flow properties for consistent blending
- Hydration behavior and stability of apixaban under manufacturing conditions
- Cross-contamination controls for high-potency anticoagulant active ingredients
- Tablet hardness, disintegration, dissolution, and content uniformity
CDMOs typically manage compliance by:
- Supplier qualification of the API site and lot release documentation
- Incoming QC (identity, assay, impurity screen) and blending verification
- In-process controls aligned to the approved manufacturing process
- Stability program execution under ICH conditions and post-change risk assessments
What intermediates and process steps drive apixaban supply bottlenecks?
Apixaban manufacturing depends on complex heterocycle synthesis and purification steps that are sensitive to:
- Reaction yields and chromatography or crystallization throughput
- Batch-to-batch impurity formation (process chemistry control)
- Solvent availability and drying capability for crystallization steps
- Filtering and washing capacity (wet cake handling and residual solvent controls)
Supply bottlenecks usually appear when:
- a key intermediate production line is capacity-limited
- solvent or drying capacity is constrained
- impurity specifications become tighter due to regulatory scrutiny or process change
What Orange Book or FDA listing does apixaban relate to for supplier qualification?
Apixaban is marketed as Eliquis (Bristol Myers Squibb and Pfizer). Supplier qualification for generics or authorized manufacturing generally ties to:
- FDA reference product manufacturing controls and comparability expectations for finished dosage forms
- DMF referencing for API manufacturing and controls
- cGMP status of API and finished product sites
A supplier list and exact listing mapping cannot be completed from the provided prompt alone.
What patent and litigation risk affects apixaban manufacturing outsourcing?
Supplier arrangements for apixaban must account for:
- Method-of-manufacture and formulation IP that can restrict certain process variants
- Generic and biosimilar-like pathways (apixaban is small molecule; the relevant risk is generic exclusivity and Paragraph IV for solid oral products)
- Settlement agreements that can affect launch timing for certain applicants
A precise litigation-and-IP risk map requires case-by-case docket data not provided in the prompt.
When do apixaban exclusivity or patent windows expire for generics, and how does that affect suppliers?
Timeline-based supplier ramp planning depends on:
- Patent expiration dates and any pediatric exclusivity extensions
- Disposition of Paragraph IV challenges
- Orange Book-listed patents by dosage strength
A specific apixaban exclusivity timeline cannot be produced from the supplied prompt alone.
Which generic manufacturers compete with Eliquis and how does that change supply strategy?
Competitive pressure influences sourcing strategy by:
- expanding the number of qualified API suppliers to reduce single-site risk
- using dual-source API programs and multiple CDMO backup facilities
- adopting robust change-control and comparability packages
A specific set of competing generic manufacturers and their sourcing strategies cannot be produced from the supplied prompt alone.
What manufacturing/IP barriers block new apixaban API entrants?
New entrants typically face barriers in:
- Establishing a reproducible, impurity-controlled synthesis route at scale
- Passing regulatory scrutiny for DMF completeness and batch consistency
- Achieving validated polymorph and particle-size ranges
- Securing sufficient capacity for critical purification steps
- Managing IP constraints on key intermediates or process steps
A detailed barrier map requires supplier- and route-specific patent and regulatory analysis not included in the prompt.
Key Takeaways
- Apixaban supply is managed through an API-to-finished-dose chain requiring tight impurity, particle-size, and cGMP controls.
- Supplier contracts are typically structured around API release specs, quality agreements, and change-control commitments, with separate CDMO manufacturing responsibility for tablet production.
- A verified, named supplier roster for apixaban API and DMF holders cannot be compiled from the provided prompt alone.
- Procurement and risk management for apixaban should prioritize DMF suitability, impurity profile adherence, change-control history, and redundancy across API and solid-dose capacity.
FAQs
- How do I qualify an apixaban API supplier for FDA submissions?
- What impurity profile matters most in apixaban API release specifications?
- Which solid-dose manufacturing parameters most affect apixaban tablet dissolution and content uniformity?
- How should apixaban suppliers design change-control for crystallization and polymorph transitions?
- What supply-chain risk controls reduce batch failures for anticoagulant APIs like apixaban?
References (APA)
- [No sources were provided in the prompt.]
